[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma

Weber, Damien Charles; Zilli, Thomas; Buchegger, Franz; Casanova, Nathalie; Haller, Guy; Rouzaud, Michel; Nouet, Philippe; Dipasquale, G.; Ratib, Osman; Zaidi, Habib; Vees, Hansjörg; Miralbell, Raymond

doi:10.1186/1748-717x-3-44

Cited by 118 publications

(60 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the fluorinated amino acid analog 18 F-FET has emerged as a powerful complementary tool for glioma imaging (21,22). 18 F-FET PET was shown to be useful for biopsy and treatment planning by accurate delineation of the tumor borders and demarcation of most malignant tumor parts (11,21,(23)(24)(25) and for subsequent treatment monitoring including differentiation between benign therapyinduced changes and tumor recurrence (13,18,(26)(27)(28). Furthermore, the additional use of kinetic analysis of 18 F-FET PET was shown to enable more accurate tumor grading, even in individual patients: increasing time-activity curves are considered to be associated with less malignant low-grade glioma tissue, whereas decreasing timeactivity curves were shown to be prevalent in more aggressive high-grade glioma tissue (9,10).…”

Section: Discussionmentioning

confidence: 99%

Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

Jansen¹,

Suchorska

Wenter³

et al. 2013

J Nucl Med

128

View full text Add to dashboard Cite

Because the clinical course of low-grade gliomas in the individual adult patient varies considerably and is unpredictable, we investigated the prognostic value of dynamic 18 F-fluorethyltyrosine ( 18 F-FET) PET in the early diagnosis of astrocytic low-grade glioma (World Health Organization grade II). Methods: Fifty-nine patients with newly diagnosed low-grade glioma and dynamic 18 F-FET PET before histopathologic assessment were retrospectively investigated. 18 F-FET PET analysis comprised a qualitative visual classification of lesions; assessment of the semiquantitative parameters maximal, mean, and total standardized uptake value as ratio to background and biologic tumor volume; and dynamic analysis of intratumoral 18 F-FET uptake over time (increasing vs. decreasing time-activity curves). The correlation between PET parameters and progression-free survival, overall survival, and time to malignant transformation was investigated. Results: 18 F-FET uptake greater than the background level was found in 34 of 59 tumors. Dynamic 18 F-FET uptake analysis was available for 30 of these 34 patients. Increasing and decreasing timeactivity curves were found in 18 and 12 patients, respectively. Neither the qualitative factor presence or absence of 18 F-FET uptake nor any of the semiquantitative uptake parameters significantly influenced clinical outcome. In contrast, decreasing time-activity curves in the kinetic analysis were highly prognostic for shorter progression-free survival and time to malignant transformation (P , 0.001). Conclusion: Absence of 18 F-FET uptake in newly diagnosed astrocytic low-grade glioma does not generally indicate an indolent disease course. Among the 18 F-FET-positive gliomas, decreasing time-activity curves in dynamic 18 F-FET PET constitute an unfavorable prognostic factor in astrocytic low-grade glioma and, by identifying high-risk patients, may ease treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

Jansen¹,

Suchorska

Wenter³

et al. 2013

J Nucl Med

128

View full text Add to dashboard Cite

show abstract

“…For this application, amino acid and nucleoid tracers are better suited (123)(124)(125)(126)(127). Several studies suggested that outcomes are better for patients in whom 11 C-MET or 18 F-FET PET coregistered to MRI are applied for treatment planning and follow-up than for patients diagnosed by MRI alone (123)(124)(125)(126)128). In the follow-up and for the management of patients with brain tumor, the differentiation between recurrent tumor as a sign of treatment failure and necrosis as an indicator of success is essential.…”

Section: Monitoring Treatment Effects Petmentioning

confidence: 99%

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Heiss¹,

Raab²,

Lanfermann³

2011

J Nucl Med

126

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the differences in the information obtained by various MRI and PET modalities and (2) the best combination of imaging procedures to detect brain tumors, to define the biologic activity or malignancy of a tumor, to validate therapeutic effects, and to differentiate between recurrent tumor and tissue necrosis.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through October 2012.Neuroimaging plays a significant role in the diagnosis of intracranial tumors, especially brain gliomas, and must consist of an assessment of location and extent of the tumor and of its biologic activity. Therefore, morphologic imaging modalities and functional, metabolic, or molecular imaging modalities should be combined for primary diagnosis and for following the course and evaluating therapeutic effects. MRI is the gold standard for providing detailed morphologic information and can supply some additional insights into metabolism (MR spectroscopy) and perfusion (perfusion-weighted imaging) but still has limitations in identifying tumor grade, invasive growth into neighboring tissue, and treatment-induced changes, as well as recurrences. These insights can be obtained by various PET modalities, including imaging of glucose metabolism, amino acid uptake, nucleoside uptake, and hypoxia. Diagnostic accuracy can benefit from coregistration of PET results and MRI, combining the high-resolution morphologic images with the biologic information. These procedures are optimized by the newly developed combination of PET and MRI modalities, permitting the simultaneous assessment of morphologic, functional, metabolic, and molecular information on the human brain. Brai n tumors are newly formed alterations of morphology, and for their diagnosis, therefore, CT or MRI is mandatory. These imaging modalities are essential for delineating the normal and pathologic anatomy and also for assessing vascular supply and impairment of the blood-brain barrier (BBB) (perfusion-weighted imaging; contrast enhancement). Additionally, MRI is capable of giving functional information on microstructural (diffusion-weighted imaging [DWI]), physiologic, and metabolic (MR spectroscopy [MRS]) changes of tumor tissues. PET and MRI provide physiologic, biochemical, and molecular information related to tumor metabolism, proliferation rate, invasiveness, and interaction with surrounding and remote areas-informati...

show abstract

“…53 Manual delineation of target volumes using different window-level settings and look-up tables is the most common and widely used technique in the clinic; however, the method is highly operator-dependent and is subject to high variability among operators. Rather large intraobserver variability was reported 54 for many localizations, including high-grade glioma (HGG), as shown in Fig. 6.…”

Section: Pet Image Segmentation Techniquesmentioning

confidence: 92%

Novel Quantitative Techniques in Hybrid (PET-MR) Imaging of Brain Tumors

Senthamizhchelvan

Zaidi

2013

PET Clinics

Self Cite

View full text Add to dashboard Cite

[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma

Cited by 118 publications

References 40 publications

Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Novel Quantitative Techniques in Hybrid (PET-MR) Imaging of Brain Tumors

Contact Info

Product

Resources

About

[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma

Cited by 118 publications

References 40 publications

Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Novel Quantitative Techniques in Hybrid (PET-MR) Imaging of Brain Tumors

Contact Info

Product

Resources

About

Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients